<?xml version="1.0" encoding="ISO-8859-1"?>
<rss version="2.0">
    <channel>
        <title>PR.com Press Releases: Johnson &amp; Johnson News</title>
        <description>Latest news releases from PR.com for Johnson &amp;amp; Johnson.</description>
        <link>http://www.pr.com/press-releases</link>
        <lastBuildDate>Wed, 03 Dec 2008 22:39:09 -0500</lastBuildDate>
        <image>
            <url>http://www.pr.com/images/logo_white.jpg</url>
            <title>Press Releases from PR.com</title>
            <link>http://www.pr.com/</link>
            <width>68</width>
            <height>69</height>
            <description>PR.com provides Free Press Release Distribution, &amp; is a unique Directory of Businesses, Products, Services, &amp; Jobs - in all industries.  Find Full Company Profiles.</description>
        </image>
        <copyright>© 2008 PR Worldwide, Inc.</copyright>
        <ttl>60</ttl>
        <item>
            <title>INVEGA™ Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL® in Acutely Ill Hospitalized Patients</title>
            <link>http://www.pr.com/press-release/56093</link>
            <description>In a comparison study between schizophrenia treatments INVEGA™ (paliperidone) Extended-Release Tablets and SEROQUEL® (quetiapine), Invega patients saw schizophrenia symptom improvements as early as five days into therapy and continued through the end of the two-week study period. Results were presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida. [PR.com - October 13, 2007]</description>
            <author>Johnson &amp; Johnson</author>
            <guid isPermaLink="true">http://www.pr.com/press-release/56093</guid>
        </item>
    </channel>
</rss>
